A Phase I, Open-label, Cohort Dose Escalation Trial With BI 836858 in Patients With Refractory or Relapsed Acute Myeloid Leukemia and Patients With Acute Myeloid Leukemia in Complete Remission With High Risk to Relapse
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2017
At a glance
- Drugs BI 836858 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 22 Feb 2017 Planned number of patients changed from 36 to 63.
- 01 Jun 2016 Planned End Date changed from 1 Oct 2016 to 1 Mar 2019.
- 01 Jun 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Mar 2019.